AI Article Synopsis
- The study investigates the potential of adalimumab, a TNF-α blocker, as a treatment for severe COVID-19 when combined with remdesivir and dexamethasone.
- A randomized controlled trial included 68 patients, with 34 receiving adalimumab and 34 in the control group, both groups getting remdesivir and dexamethasone.
- Results showed no significant differences in mortality, mechanical ventilation needs, or hospitalization duration between the two groups, indicating adalimumab may not be effective for severe COVID-19 cases.
Article Abstract
Background: COVID-19, which is a disease caused by the SARS-CoV-2 virus, has spread around the world since late 2019. Studies have found associations between the rising levels of TNF-α and severe COVID-19 cases. Hence, TNF-α blocking can possibly be a favorable intervention in modifying COVID-19. To this end, in order to manage pneumonia caused by COVID-19, adalimumab may potentially be considered as a potential therapeutic agent. The present study aimed to investigate the potential therapeutic role of adalimumab in treating COVID-19 cases in combination therapy with remdesivir and dexamethasone.
Methods: Among the 68 patients who were included in the current randomized controlled trial, 34 were assigned to the adalimumab group and the remaining 34 were assigned to the control group. Adalimumab at a dose of 40 mg, subcutaneous for once, was used for the intervention group. Both the intervention and control groups received remdesivir, dexamethasone, and supportive care. The data gathered to make comparisons of the groups included demographic information, the rate of mortality, mechanical ventilation requirement, length of stay in hospital and Intensive Care Unit (ICU), and imaging findings.
Results: There was no significant difference between the two groups in the terms of mortality rate (P-value = 1) and mechanical ventilation requirement (P-value = 1). The length of hospital and ICU stay as well as radiologic changes were not affected either (P-value = 1, 0.27, and 0.53, respectively).
Conclusions: Our findings did not support the use of adalimumab in combination with remdesivir and dexamethasone in the treatment of severe COVID-19 cases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260560 | PMC |
| http://dx.doi.org/10.1016/j.intimp.2021.107961 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of COVID-19 on testing, positive cases, patient characteristics, and hospital contacts for respiratory syncytial virus, influenza, and pneumococcus in Danish children.
J Infect Public Health
January 2025
Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Mary Elizabeth's Hospital, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Electronic address:
Background: Respiratory infections substantially impact pediatric health. The COVID-19 pandemic introduced widespread non-pharmaceutical interventions, which influenced the incidence of common respiratory infections. This comprehensive study investigates the impact of these interventions on the incidence of respiratory syncytial virus, influenza, and invasive pneumococcal disease in Danish children.
View Article and Find Full Text PDFRisk Factors for Disseminated Tuberculosis and Associated Survival in Adults Without Human Immunodeficiency Virus.
Open Forum Infect Dis
January 2025
Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Background: The global resurgence of disseminated tuberculosis (TB) after the coronavirus disease 2019 pandemic highlights the necessity of understanding host risk factors, especially in adults without human immunodeficiency virus.
Methods: We reviewed TB cases admitted to Shanghai Public Health Clinical Center from 2017 to 2022. We analyzed baseline characteristics and outcomes.
Socioeconomic correlates of urban mobility trends in two Australian cities during transitional periods of the COVID-19 pandemic.
R Soc Open Sci
January 2025
School of Computing and Information Systems, The University of Melbourne, Parkville, Victoria, Australia.
During the COVID-19 pandemic, both government-mandated lockdowns and discretionary changes in behaviour combined to produce dramatic and abrupt changes to human mobility patterns. To understand the socioeconomic determinants of intervention compliance and discretionary behavioural responses to epidemic threats, we investigate whether changes in human mobility showed a systematic variation by socioeconomic status during two distinct periods of the COVID-19 pandemic in Australia. We analyse mobility data from two major urban centres and compare the trends during mandated stay-at-home policies and after the full relaxation of nonpharmaceutical interventions, which coincided with a large surge of COVID-19 cases.
View Article and Find Full Text PDFThe succession of One Day Surgery with Breast Cancer Home Recovery Program by the National Cancer Institute (ODS BHR NCI) during the COVID-19 pandemic in Thailand.
Surg Open Sci
January 2025
Division of Breast Cancer Surgery, Department of Surgery, National Cancer Institute, Bangkok, Thailand.
Background: Breast cancer is the most common cancer among women. In response to the need to hospital stays and minimize waiting time for surgery, particularly during the COVID-19 pandemic, the National Cancer Institute developed the One Day Surgery with Breast cancer Home Recovery program (ODS BHR NCI). The aim of study is to assess the success rate of breast cancer surgeries conducted through this program and to evaluate the incidence of complications.
View Article and Find Full Text PDFUnveiling autism spectrum disorder in South East Asia through a public health Lens.
Front Child Adolesc Psychiatry
December 2024
Department of Community and Family Medicine, All India Institute of Medical Sciences, Deoghar (AIIMS Deoghar), Deoghar, India.
Autism spectrum disorder (ASD) is a multifaceted developmental condition characterized by persistent challenges in social communication, restricted interests, and repetitive behaviors. Though there is no cure, early and intensive interventions can significantly improve the quality of life for those affected. The aim of this paper is to examine the complexities of autism spectrum disorder (ASD) from a public health perspective in South East Asian region, highlighting the global rise in prevalence and the compounded challenges posed by the COVID-19 pandemic.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!